信达生物(01801.HK) 公布,伊匹木单抗注射液(抗细胞毒T淋巴细胞相关抗原4 (CTLA-4)单抗,研发代号:IBI310)联合信迪利单抗用于可切除的微卫星高度不稳定型(MSI-H)或错配修复缺陷型(dMMR)结肠癌患者的新辅助治疗的新药上市申请(NDA),已获中国国家药监局药品审评中心受理并纳入优先审评程序。
伊匹木单抗是首个递交NDA的中国研发的CTLA-4单抗,同时也是信迪利单抗奠定其肿瘤免疫治疗领先品牌的又一里程碑。(jl/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-21 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.